Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug...

|By:, SA News Editor

Pharmacyclics (PCYC -0.6%) enrolls a fifth patient in a Phase III trial of its ibrutinib drug for treating forms of leukemia or lymphoma and triggers a third $50M milestone payment from J&J (JNJ) unit Janssen Biotech. The company may receive up to an extra $675M in milestones, bringing total upfront and milestone payments to $975M. (PR)